Scholarlink

<p>Pancreatic cancer is a highly aggressive malignancy that is often diagnosed at an advanced stage, largely due to the lack of reliable biomarkers for early diagnosis. Stromal cell–derived factor 4 (SDF4) is a secreted calcium-binding protein localized to the Golgi apparatus and has been implicated in various tumor types; however, its clinical relevance in pancreatic cancer remains unclear. In this study, we evaluated the diagnostic potential of circulating SDF4 in a hospital-based case–control study in Japan, including 124 patients with pancreatic cancer (stage I–IV) and 125 matched controls. Plasma SDF4 levels were significantly elevated in patients compared with controls (p &lt; 0.0001), including those with early-stage disease (stage I–II). Receiver operating characteristic analysis showed an area under the curve (AUC) of 0.82 for all stages and 0.81 for early-stage disease. Compared with CA19-9, SDF4 showed superior performance in early-stage disease, and the combination of SDF4 and CA19-9 improved diagnostic performance. These findings suggest that circulating SDF4 is a promising diagnostic marker for early-stage pancreatic cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Circulating SDF4 as a potential diagnostic marker for early-stage pancreatic cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月29日

查看全文
  • Itsuki Kageyama,
  • Yingsong Lin,
  • Naoki Sasahira,
  • Masato Ozaka,
  • Takashi Sasaki,
  • Makoto Ueno,
  • Hiroshi Ishii,
  • Naoto Egawa,
  • Yasushi Adachi,
  • Tae Sasakabe,
  • Sayo Kawai,
  • Masahiro Nakatochi,
  • Hiroya Yamada,
  • Mitsuro Kanda,
  • Shogo Kikuchi,
  • Asahi Hishida

摘要

Pancreatic cancer is a highly aggressive malignancy that is often diagnosed at an advanced stage, largely due to the lack of reliable biomarkers for early diagnosis. Stromal cell–derived factor 4 (SDF4) is a secreted calcium-binding protein localized to the Golgi apparatus and has been implicated in various tumor types; however, its clinical relevance in pancreatic cancer remains unclear. In this study, we evaluated the diagnostic potential of circulating SDF4 in a hospital-based case–control study in Japan, including 124 patients with pancreatic cancer (stage I–IV) and 125 matched controls. Plasma SDF4 levels were significantly elevated in patients compared with controls (p < 0.0001), including those with early-stage disease (stage I–II). Receiver operating characteristic analysis showed an area under the curve (AUC) of 0.82 for all stages and 0.81 for early-stage disease. Compared with CA19-9, SDF4 showed superior performance in early-stage disease, and the combination of SDF4 and CA19-9 improved diagnostic performance. These findings suggest that circulating SDF4 is a promising diagnostic marker for early-stage pancreatic cancer.